^
    Back
    Association details:
    Biomarker:CXCL8-L
    Cancer:Ovarian Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Gynecol Oncol
    Title:

    Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment

    Published date:
    07/31/2020
    Excerpt:
    This phase II study tested bevacizumab plus sorafenib in two cohorts; bevacizumab-naïve and bevacizumab-exposed patients. Pretreatment low IL8 concentration was associated with PFS ≥ 4 months (p = .031).
    DOI:
    10.1016/j.ygyno.2020.07.031